Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia
US11858995B2 · kind B2 · utility
0Cited by
30References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 22, 2021 |
| Grant date | Jan 2, 2024 |
| Priority date | — |
| Expiry date | Dec 22, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/565
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are methods of clinical treatment of chronic lymphoblastic leukemia (CLL) in human subjects using a bispecific antibody which binds to CD3 and CD20.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.